What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

mTOR Signaling in Growth Control and Disease

Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · see citing works

Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor

Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 6,535 · see citing works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works

Wnt/β-Catenin Signaling in Development and Disease

Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568 · see citing works

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · see citing works

Wnt signalling in stem cells and cancer

Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

Regulation of Cell Death Protease Caspase-9 by Phosphorylation

Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E. J., Frisch, S. M., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 3,118 · see citing works

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · see citing works

Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation

Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103 · see citing works

Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA

Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953 · see citing works

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes &amp; Development · doi:10.1101/gad.1110003 · Cited by 1,911 · see citing works

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · see citing works

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · see citing works

Translational control in stress and apoptosis

Holčı́k, M., & Sonenberg, N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1618 · Cited by 1,366 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

The nuts and bolts of AGC protein kinases

Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294 · see citing works

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · see citing works

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C. H., Koutcher, J. A., Scher, H. I., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,197 · see citing works

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,185 · see citing works

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · see citing works

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · see citing works

The emerging roles of forkhead box (Fox) proteins in cancer

Myatt, S. S., & Lam, E. W. ‐. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2223 · Cited by 1,065 · see citing works

Protein Kinase B Kinases That Mediate Phosphatidylinositol 3,4,5-Trisphosphate-Dependent Activation of Protein Kinase B

Stephens, L., Anderson, K. E., Stokoe, D., Erdjument‐Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F. P., Tempst, P., et al. (1998) · Science · doi:10.1126/science.279.5351.710 · Cited by 1,061 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

Diverse somatic mutation patterns and pathway alterations in human cancers

Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,018 · see citing works

Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate

Whitman, M., Downes, C. P., Keeler, M. L., Keller, T. L., & Cantley, L. C. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,018 · see citing works

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993 · see citing works

Internal ribosome entry sites in eukaryotic mRNA moleculesPreprint

Hellen, C. U. T., & Sarnow, P. (2001) · Genes & Development · doi:10.1101/gad.891101 · Cited by 977 · see citing works

Akt regulates growth by directly phosphorylating Tsc2

Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959 · see citing works

Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin

Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 959 · see citing works

Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation

NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/bj3440427 · Cited by 926 · see citing works

c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaPreprint

Weng, A. P., Millholland, J. M., Yashiro–Ohtani, Y., Arcangeli, M.-L., Lau, A. N., Wai, C., Bianco, C. D., Rodríguez, C. G., Sai, H., Tobias, J. W., et al. (2006) · Genes & Development · doi:10.1101/gad.1450406 · Cited by 863 · see citing works

Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival

Liao, X., Lochhead, P. J., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 842 · see citing works

NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth

Palomero, T., Lim, W. K., Odom, D. T., Sulis, M. L., Real, P. J., Margolin, A. A., Barnes, K., O’Neil, J., Neuberg, D. S., Weng, A. P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606108103 · Cited by 821 · see citing works

Translational control in cancer

Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2824 · Cited by 820 · see citing works

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 813 · see citing works

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787 · see citing works

Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

Whitman, M., Kaplan, D., Schaffhausen, B., Cantley, L., & Roberts, T. (1985) · Nature · doi:10.1038/315239a0 · Cited by 732 · see citing works

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730 · see citing works

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K. M., Herrmann, R., Lynch, K., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649 · see citing works

A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T. Q., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 632 · see citing works

Class I PI3K in oncogenic cellular transformation

Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 598 · see citing works

Targeting the PI3K signaling pathway in cancer

Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics &amp; Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543 · see citing works

Oncogenic Mutations of PIK3CA in Human Cancers

Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 539 · see citing works

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Tsimberidou, A. M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 538 · see citing works

Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells

Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 505 · see citing works

Circumventing cancer drug resistance in the era of personalized medicine

Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · see citing works

Balancing Akt with S6K

Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 474 · see citing works

The Akt kinases: Isoform specificity in metabolism and cancer

Gonzalez, E., & McGraw, T. E. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9335 · Cited by 474 · see citing works

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D. M., Sanchez, V. M., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W. J., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 469 · see citing works

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448 · see citing works

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437 · see citing works

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · see citing works

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

Tenbaum, S. P., Ordóñez‐Morán, P., Puig, I., Chicote, I., Arqués, O., Landolfi, S., Fernández, Y., Herance, J. R., Gispert, J. D., Mendizabal, L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2772 · Cited by 386 · see citing works

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

Muranen, T. E., Selfors, L. M., Worster, D. T., Iwanicki, M., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 385 · see citing works

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374 · see citing works

A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA.

Sonenberg, N., Morgan, M. A., Merrick, W. C., & Shatkin, A. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.10.4843 · Cited by 367 · see citing works

Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner

Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., SCHAEFER, E. M., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 361 · see citing works

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Jankú, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M. T., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300 · see citing works

4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 272 · see citing works

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

Liu, P., Cheng, H.-L. M., Santiago, S., Raeder, M. B., Zhang, F., Isabella, A. J., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 258 · see citing works

Prognostic Role of <i>PIK3CA</i> Mutation in Colorectal Cancer: Cohort Study and Literature Review

Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258 · see citing works

Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc.

Rosenwald, I. B., Rhoads, D. B., Callanan, L., Isselbacher, K. J., & Schmidt, E. V. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6175 · Cited by 256 · see citing works

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cortés, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K. A., Pivot, X. B., Verma, S., Albanell, J., Conte, P., Lluch, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 250 · see citing works

PTEN Level in Tumor Suppression: How Much Is Too Little?

Carracedo, A., Alimonti, A., & Pandolfi, P. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2488 · Cited by 244 · see citing works

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., & Bentires‐Alj, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.023 · Cited by 242 · see citing works

An Essential E Box in the Promoter of the Gene Encoding the mRNA Cap-Binding Protein (Eukaryotic Initiation Factor 4E) Is a Target for Activation by c-myc

Jones, R. M., Branda, J. A., Johnston, K. A., Polymenis, M., Gadd, M. A., Rustgi, A. K., Callanan, L., & Schmidt, E. V. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4754 · Cited by 237 · see citing works

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

Ilić, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 213 · see citing works

Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

Choo, A. Y., & Blenis, J. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7659 · Cited by 213 · see citing works

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Liu, Q., Xu, C., Kirubakaran, S., Zhang, X., Hur, W., Liu, Y., Kwiatkowski, N. P., Wang, J., Westover, K. D., Gao, P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1702 · Cited by 212 · see citing works

Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 170 · see citing works

Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway

Guo, S., & Sonenshein, G. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8681-8690.2004 · Cited by 169 · see citing works

A second look at cellular mRNA sequences said to function as internal ribosome entry sites

Kozak, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki958 · Cited by 167 · see citing works

The role of c-myc in regulation of translation initiation

Schmidt, E. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207548 · Cited by 166 · see citing works

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Šmída, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165 · see citing works

High‐resolution genomic and expression analyses of copy number alterations in breast tumors

Haverty, P. M., Fridlyand, J., Li, L., Getz, G. A., Beroukhim, R., Lohr, S., Wu, T. D., Cavet, G., Zhang, Z., & Chant, J. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20558 · Cited by 158 · see citing works

Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor

Hellyer, N. J., Kim, M.-S., & Koland, J. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102079200 · Cited by 154 · see citing works

EphB/EphrinB Receptors and Wnt Signaling in Colorectal Cancer

Clevers, H. C., & Batlle, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3849 · Cited by 152 · see citing works

Protein synthesis in eukaryotes: The growing biological relevance of cap-independent translation initiation

López‐Lastra, M., RIVAS, A., & Barría, M. I. (2005) · Biological Research · doi:10.4067/s0716-97602005000200003 · Cited by 147 · see citing works

ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase

Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144 · see citing works

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Manzoli, L., & McCubrey, J. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903136775 · Cited by 120 · see citing works

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

Chiarini, F., Falà, F., Tazzari, P. L., Ricci, F., Astolfi, A., Pession, A., Pagliaro, P., McCubrey, J. A., & Martelli, A. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4884 · Cited by 119 · see citing works

PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy

McIntyre, J. B., Wu, J. S.-Y., Craighead, P. S., Phan, T., Köbel, M., Lees‐Miller, S. P., Ghatage, P., Magliocco, A. M., & Doll, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.019 · Cited by 117 · see citing works

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

Shuttleworth, S. J., Silva, F. A., Cecil, A., Tomassi, C., Hill, T., Raynaud, F. I., Clarke, P. A., & Workman, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011229 · Cited by 103 · see citing works

Resist or die: FOXO transcription factors determine the cellular response to chemotherapy

Gomes, A., Brosens, J. J., & Lam, E. W. ‐. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6920 · Cited by 94 · see citing works

Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice

Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1637 · Cited by 85 · see citing works

Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer

Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 79 · see citing works

Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia

Mansour, M. R., Duke, V. M., Foroni, L., Patel, B., Allen, C. G., Ancliff, P. J., Gale, R. E., & Linch, D. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1474 · Cited by 79 · see citing works

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

Shepherd, C., Banerjee, L., Cheung, C. W., Mansour, M. R., Jenkinson, S., Gale, R. E., & Khwaja, A. (2012) · Leukemia · doi:10.1038/leu.2012.285 · Cited by 76 · see citing works

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma

Suda, T., Hama, T., Kondo, S., Yuza, Y., Yoshikawa, M., Urashima, M., Kato, T., & Moriyama, H. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-416 · Cited by 66 · see citing works

Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase

Mo, J., Ann, E., Yoon, J.-H., Jung, J., Choi, Y., Kim, H.-Y., Ahn, J., Kim, S., Kim, M., Hong, J.-A., et al. (2010) · Journal of Cell Science · doi:10.1242/jcs.073924 · Cited by 63 · see citing works

PI3 kinase inhibitors in the clinic: an update.

Kurtz, J., & Ray-Coquard, I. L. (2012) · PubMed · Cited by 55 · see citing works

IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress

Lewis, S. M., & Holčı́k, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401602 · Cited by 54 · see citing works

687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer

Tenbaum, S. P., Ordóñez‐Morán, P., Puig, I., Chicote, I., Arqués, O., Vivancos, A. P., Baselga, J. M., Tabernero, J. M., Munoz, A., & Pálmer, H. G. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71330-8 · Cited by 50 · see citing works

Phosphoinositides Are Essential Coactivators for p21-Activated Kinase 1

Strochlic, T. I., Viaud, J., Rennefahrt, U. E. E., Anastassiadis, T., & Peterson, J. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.015 · Cited by 50 · see citing works

PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas

Walsh, K. J., McKinney, M. S., Love, C., Liu, Q., Fan, A., Patel, A., Smith, J., Beaven, A., Jima, D. D., & Davé, S. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1060 · Cited by 49 · see citing works

Down‐regulation of Notch‐dependent transcription by Akt in vitro

Song, J., Park, S., Kim, M., & Shin, I. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.024 · Cited by 40 · see citing works

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,716 · see citing works

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,349 · see citing works

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 680 · see citing works

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 581 · see citing works

Clinical management of breast cancer heterogeneity

Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 572 · see citing works

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290 · see citing works

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273 · see citing works

A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Rebecca, V. W., Nicastri, M. C., McLaughlin, N. P., Fennelly, C., Mcafee, Q. W., Ronghe, A. M., Nofal, M., Lim, C.-Y., Witze, E. S., Chude, C. I., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0741 · Cited by 209 · see citing works

Drugging PI3K in cancer: refining targets and therapeutic strategies

Yap, T. A., Bjerke, L. M., Clarke, P. A., & Workman, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.016 · Cited by 204 · see citing works

PI3K inhibitors: review and new strategies

Zhang, M., Jang, H., & Nussinov, R. (2020) · Chemical Science · doi:10.1039/d0sc01676d · Cited by 182 · see citing works

mTOR signaling in tumorigenesis

Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167 · see citing works

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 141 · see citing works

Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs

Gerdes, H., Casado, P., Dokal, A. D., Hijazi, M., Akhtar, N., Osuntola, R., Rajeeve, V., Fitzgibbon, J., Travers, J., Britton, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22170-8 · Cited by 132 · see citing works

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

Masui, K., Tanaka, K., Ikegami, S., Villa, G. R., Yang, H., Yong, W. H., Cloughesy, T. F., Yamagata, K., Arai, N., Cavenee, W. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511759112 · Cited by 123 · see citing works

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Fusco, N., Malapelle, U., Fassan, M., Marchiò, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P. G., Tos, A. P. D., Maiorano, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644737 · Cited by 121 · see citing works

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3697 · Cited by 106 · see citing works

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

Fruman, D. A., & Cantley, L. C. (2014) · New England Journal of Medicine · doi:10.1056/nejme1400055 · Cited by 98 · see citing works

MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling

Wang, W., Shen, T., Dong, B., Creighton, C. J., Meng, Y., Zhou, W., Shi, Q., Zhou, H., Zhang, Y., Moore, D. D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97712 · Cited by 96 · see citing works

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

Brun, S., Bestion, E., Raymond, É., Bassissi, F., Jílková, Z. M., Mezouar, S., Rachid, M., Novello, M., Tracz, J., Hamaï, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1988357 · Cited by 94 · see citing works

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer

Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90 · see citing works

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities

Li, T., & Wang, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018856 · Cited by 84 · see citing works

G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway

Law, N. C., White, M. F., & Hunzicker-Dunn, M. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763235 · Cited by 79 · see citing works

Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations

Yang, W., Raufi, A. G., & Klempner, S. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.003 · Cited by 78 · see citing works

Translational and clinical implications of the genetic landscape of prostate cancer

Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 77 · see citing works

Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants

Çört, A., Özben, T., Saso, L., Luca, C. D., & Korkina, L. G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4251912 · Cited by 77 · see citing works

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Schafer, J. M., Lehmann, B. D., Ericsson, P. I. G., Marshall, C. B., Beeler, J. S., Redman, L. N., Jin, H., Sanchez, V. M., Stubbs, M. C., Scherle, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8275 · Cited by 71 · see citing works

A genome-wide single nucleotide polymorphism and copy number variation analysis for number of piglets born alive

Stafuzza, N. B., Silva, R. M. D. O., Fragomeni, B. D. O., Masuda, Y., Huang, Y., Gray, K. A., & Lourenco, D. A. L. (2019) · BMC Genomics · doi:10.1186/s12864-019-5687-0 · Cited by 70 · see citing works

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Kim, S. T., Kim, S., Klempner, S. J., Yoon, J. Y., Kim, N., Ahn, S., Bang, H., Kim, K., Park, W., Park, S. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw669 · Cited by 69 · see citing works

The role of mTOR in age-related diseases

Chrienová, Ž., Nepovimová, E., & Kuča, K. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1955873 · Cited by 68 · see citing works

Empirical inference of circuitry and plasticity in a kinase signaling network

Wilkes, E. H., Terfve, C., Gribben, J. G., Sáez-Rodríguez, J., & Cutillas, P. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423344112 · Cited by 67 · see citing works

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A. M., Barozzi, P., Petricoin, E. F., Liotta, L. A., Milani, G., Giordan, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.123 · Cited by 67 · see citing works

Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation

Cairns, J., Fridley, B. L., Jenkins, G. D., Zhuang, Y., Yu, J., & Wang, L. (2018) · EMBO Reports · doi:10.15252/embr.201744767 · Cited by 65 · see citing works

Cross-talk between the CK2 and AKT signaling pathways in cancer

Ruzzene, M., Bertacchini, J., Toker, A., & Marmiroli, S. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.03.002 · Cited by 61 · see citing works

Metabolism of Proliferating Cells.Preprint

Chandel, N. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040618 · Cited by 47 · see citing works

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects

Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61 · see citing works

MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT

Shen, T., Wang, W., Zhou, W., Coleman, I. M., Cai, Q., Dong, B., Ittmann, M., Creighton, C. J., Bian, Y., Meng, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135465 · Cited by 58 · see citing works

FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance

Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 57 · see citing works

TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer

Agarwal, N., Rinaldetti, S. L., Cheikh, B. B., Zhou, Q., Hass, E. P., Jones, R. T., Joshi, M. U., LaBarbera, D. V., Knott, S., Cech, T. R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102423118 · Cited by 56 · see citing works

Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer

Boonyaratanakornkit, V., Hamilton, N. M., Márquez‐Garbán, D. C., Pateetin, P., McGowan, E. M., & Pietras, R. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.010 · Cited by 51 · see citing works

Pharmacogenomics of Scopoletin in Tumor Cells

Seo, E., Saeed, M. E. M., Law, B. Y. K., Wu, A., Kadioglu, O., Greten, H. J., & Efferth, T. (2016) · Molecules · doi:10.3390/molecules21040496 · Cited by 51 · see citing works

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 50 · see citing works

Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers

Thomas, C., Henry, W. S., Cuiffo, B., Collmann, A. Y., Marangoni, E., Benhamo, V., Bhasin, M., Fan, C., Fuhrmann, L., Baldwin, A. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aah4674 · Cited by 50 · see citing works

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications

Martínez‐Ciarpaglini, C., Fleitas, T., Gambardella, V., Llorca, M., Mongort, C., Mengual, R., Nieto, G., Navarro, L., Huerta, M., Roselló, S., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000470 · Cited by 49 · see citing works

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers

Packer, L., Geng, X., Bonazzi, V., Ju, R. J., Mahon, C. E., Cummings, M. C., Stephenson, S., & Pollock, P. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0415 · Cited by 48 · see citing works

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

Echeverry, N., Ziltener, G., Barbone, D., Weder, W., Stahel, R. A., Broaddus, V. C., & Felley‐Bosco, E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.124 · Cited by 48 · see citing works

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds

Carrella, D., Manni, I., Tumaini, B., Dattilo, R., Papaccio, F., Mutarelli, M., Sirci, F., Amoreo, C. A., Mottolese, M., Iezzi, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11318 · Cited by 47 · see citing works

Emerging molecular classifications and therapeutic implications for gastric cancer

Chen, T., Xu, X., & Zhou, P. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0111-5 · Cited by 47 · see citing works

miR-100-5p Downregulates mTOR to Suppress the Proliferation, Migration, and Invasion of Prostate Cancer Cells

Li, S.-L., Ye, Y., & Wang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578948 · Cited by 43 · see citing works

Role of phosphoproteomics in the development of personalized cancer therapies

Cutillas, P. R. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400104 · Cited by 42 · see citing works

Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays

Wade, J. H., Alsop, A. T., Vertin, N. R., Yang, H. W., Johnson, M. D., & Bailey, R. C. (2015) · ACS Central Science · doi:10.1021/acscentsci.5b00250 · Cited by 41 · see citing works

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R

de Lint, K., Poell, J. B., Soueidan, H., Jastrzebski, K., Rodriguez, J. V., Lieftink, C., Wessels, L. F. A., & Beijersbergen, R. L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0865 · Cited by 40 · see citing works

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

Sathe, A., Guerth, F. M., Cronauer, M. V., Heck, M. M., Thalgott, M. K., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.534 · Cited by 39 · see citing works

Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer

Waugh, M. G. (2014) · Journal of Cancer · doi:10.7150/jca.9794 · Cited by 37 · see citing works

An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors

Wu, D., Yan, Y., Wei, T., Ye, Z., Xiao, Y., Pan, Y., Orme, J. J., Wang, D., Wang, L., Ren, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108744 · Cited by 37 · see citing works

mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

Pazhooh, R. D., Farnood, P. R., Asemi, Z., Mirsafaei, L., Yousefi, B., & Mirzaei, H. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103142 · Cited by 36 · see citing works

Principles of dormancy evident in high-grade serous ovarian cancer

Shepherd, T. G., & Dick, F. A. (2022) · Cell Division · doi:10.1186/s13008-022-00079-y · Cited by 37 · see citing works

Small molecule targeting of SHIP1 and SHIP2

Kerr, W. G., Pedicone, C., Dormann, S., Pacherille, A., & Chisholm, J. D. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190775 · Cited by 36 · see citing works

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma

Ross, R. L., McPherson, H. R., Kettlewell, L., Shnyder, S. D., Hurst, C. D., Alder, O., & Knowles, M. A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2570-0 · Cited by 35 · see citing works

ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma

Yun, M. R., Choi, H., Kang, H., Lee, Y., Joo, H., Kim, D. H., Kim, H. R., Hong, M. H., Yoon, S. O., & Cho, B. C. (2017) · Oncogene · doi:10.1038/onc.2017.339 · Cited by 35 · see citing works

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers

Harding, J. J., Awada, A. H., Roth, G. S., Decaens, T., Merle, P., Kotecki, N., Dreyer, C., Ansaldi, C., Rachid, M., Mezouar, S., et al. (2022) · Liver Cancer · doi:10.1159/000522418 · Cited by 34 · see citing works

Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection

Labots, M., van der Mijn, J. C., Beekhof, R., Piersma, S. R., Haas, R. R. D. G., Pham, T. V., Knol, J. C., Dekker, H., van Grieken, N. C. T., Verheul, H. M. W., et al. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.04.014 · Cited by 34 · see citing works

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas

Janus, J. M., O’Shaughnessy, R. F. L., Harwood, C. A., & Maffucci, T. (2017) · Cancers · doi:10.3390/cancers9070086 · Cited by 34 · see citing works

Pharmacogenomic Characterization of Cytotoxic Compounds from Salvia officinalis in Cancer Cells.

Kadioglu, O., & Efferth, T. (2015) · Journal of Natural Products · doi:10.1021/np501007n · Cited by 33 · see citing works

Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells

Nicastri, M. C., Rebecca, V. W., Amaravadi, R. K., & Winkler, J. D. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1395504 · Cited by 29 · see citing works

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Tran, P. N., Nguyen, C., & Klempner, S. J. (2016) · International Neurourology Journal · doi:10.5213/inj.1632740.370 · Cited by 28 · see citing works

Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice

Chen, R., Zhao, Y., Huang, Y., Yang, Q., Zeng, X., Jiang, W., Liu, J., Thrasher, J. B., Forrest, M. L., & Li, B. (2015) · The Prostate · doi:10.1002/pros.22941 · Cited by 28 · see citing works

Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion

Mavrommati, I., Cisse, O., Falasca, M., & Maffucci, T. (2016) · Scientific Reports · doi:10.1038/srep23277 · Cited by 28 · see citing works

Synergistic interactions with PI3K inhibition that induce apoptosis

Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28 · see citing works

A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine

Chen, B., & Jin, W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1200061 · Cited by 29 · see citing works

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma

Vallejo-Díaz, J., Olazabal-Morán, M., Cariaga-Martínez, A. E., Pajares, M. J., Flores, J. M., Pı́o, R., Montuenga, L. M., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13195 · Cited by 27 · see citing works

Predictive biomarkers along gastric cancer pathogenetic pathways

Panarese, I., Vita, F. D., Ronchi, A., Romano, M., Alfano, R., Martino, N. D., Marino, F. Z., Ferraraccio, F., & Franco, R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1301207 · Cited by 27 · see citing works

mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme

Ramaiah, M. J., & Kurappalli, R. K. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06462-2 · Cited by 27 · see citing works

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235

Xie, C., Freeman, M. J., Lu, H., Wang, X., Forster, C. L., Sarver, A. L., & Hallstrom, T. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16970 · Cited by 26 · see citing works

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K., Shelton, A., Patel, S. D., Limas, J. C., Skinner, K., Bash, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200014 · Cited by 25 · see citing works

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

Holzhauser, S., Lukoseviciute, M., Papachristofi, C., Vasilopoulou, C., Herold, N., Wickström, M., Kostopoulou, O. N., & Dalianis, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5167 · Cited by 24 · see citing works

Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases – potentially novel therapeutic targets

Ito, Y., Hart, J. R., & Vogt, P. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1522302 · Cited by 22 · see citing works

Targeted therapies in hepatocellular carcinoma: past, present, and future

Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 21 · see citing works

A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention

Yan, Y., Dai, T., Guo, M., Zhao, X., Chen, C., Zhou, Y., Qin, M., Xu, L., & Zhao, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132686 · Cited by 21 · see citing works

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors

Rogers, H. A., Estranero, J. G., Gudka, K., & Grundy, R. G. (2016) · Oncotarget · doi:10.18632/oncotarget.13781 · Cited by 21 · see citing works

Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells

Shi, L., Tan, X., Liu, X., Jiang, Y. L., Bota‐Rabassedas, N., Niu, Y., Luo, J., Xi, Y., Zong, C. C., Creighton, C. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023537118 · Cited by 20 · see citing works

Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes

Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021) · Cancers · doi:10.3390/cancers13133272 · Cited by 20 · see citing works

Identifying therapeutic targets in gastric cancer: the current status and future direction

Yu, B., & Xie, J. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv084 · Cited by 19 · see citing works

Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines

Kostopoulou, O. N., Holzhauser, S., Lange, B. K. A., Ohmayer, A., Andonova, T., Bersani, C., Wickström, M., & Dalianis, T. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4896 · Cited by 19 · see citing works

Circular RNA profiling in plasma exosomes from patients with gastric cancer

Rao, M., Zhu, Y., Qi, L., Hu, F., & Gao, P. (2020) · Oncology Letters · doi:10.3892/ol.2020.11800 · Cited by 19 · see citing works

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

Morrison, M. M., Williams, M. M., Vaught, D., Hicks, D. J., Lim, J., McKernan, C., Aurisicchio, L., Ciliberto, G., Simion, C., Sweeney, C. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.169 · Cited by 18 · see citing works

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms

Pandey, R., & Kapur, R. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0388-z · Cited by 18 · see citing works

Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44

Malik, N., Nirujogi, R. S., Peltier, J., Macartney, T., Wightman, M., Prescott, A. R., Gourlay, R., Trost, M., Alessi, D. R., & Karapetsas, A. (2019) · Biochemical Journal · doi:10.1042/bcj20190608 · Cited by 18 · see citing works

New insights from the widening homogeneity perspective to target intratumor heterogeneity

Tong, M., Deng, Z., Zhang, X., He, B., Yang, M., Cheng, W., & Liu, Q. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0287-y · Cited by 17 · see citing works

Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment

Pedicona, F., Casado, P., Hijazi, M., Gribben, J. G., Rouault‐Pierre, K., & Cutillas, P. R. (2022) · Science Signaling · doi:10.1126/scisignal.abl7989 · Cited by 17 · see citing works

Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity

Shymanets, A., Prajwal, P., Vadas, O., Czupalla, C., LoPiccolo, J., Brenowitz, M. D., Ghigo, A., Hirsch, E., Krause, E., Wetzker, R., et al. (2015) · Biochemical Journal · doi:10.1042/bj20150099 · Cited by 17 · see citing works

Lipid phosphatases SKIP and SHIP 2 regulate fibronectin‐dependent cell migration in glioblastoma

Ramos, A. R., Ghosh, S., Dedobbeleer, M., Robe, P. A. J. T., Rogister, B., & Erneux, C. (2019) · FEBS Journal · doi:10.1111/febs.14769 · Cited by 17 · see citing works

Advances in Palmitoylation: A key Regulator of liver cancer development and therapeutic targets

Zhu, Z., Feng, S., Zeng, A., & Song, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116810 · Cited by 15 · see citing works

Protein functional effector sncRNAs (pfeRNAs) in lung cancer

Brock, M. V., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.013 · Cited by 15 · see citing works

Synergistic induction of cell death in haematological malignancies by combined phosphoinositide‐3‐kinase and BET bromodomain inhibition

Tinsley, S., Meja, K. K., Shepherd, C., & Khwaja, A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13283 · Cited by 15 · see citing works

Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features

Kim, H. J., & Kim, D. (2020) · Molecules · doi:10.3390/molecules25204641 · Cited by 15 · see citing works

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors

Hijazi, M., Casado, P., Akhtar, N., Álvarez–Teijeiro, S., Rajeeve, V., & Cutillas, P. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100240 · Cited by 14 · see citing works

Preventive Effect of Combined Zingiber officinale and Terminalia chebula against DMBA-Induced Breast Cancer Rats via mTOR Inhibition

Mathiyazhagan, J., Ramamoorthy, S., Jayaraj, R., Madhyastha, H., & Muthukaliannan, G. K. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1903948 · Cited by 14 · see citing works

Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

Muranen, T. E., Meric‐Bernstam, F., & Mills, G. B. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.020 · Cited by 14 · see citing works

Phosphorylation, Signaling, and Cancer: Targets and Targeting

Marmiroli, S., Fabbro, D., Miyata, Y., Pierobon, M., & Ruzzene, M. (2015) · BioMed Research International · doi:10.1155/2015/601543 · Cited by 14 · see citing works

E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing

Millán‐Uclés, Á., Zuluaga, S., Marqués, M., Vallejo-Díaz, J., Sanz, L., Cariaga-Martínez, A. E., Real, F. X., & Carrera, A. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13414 · Cited by 13 · see citing works

MINI REVIEW What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the

Pathway, P. K., Klempner, S. J., Myers, A. P., & Cantley, L. C. (2016)

Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance

Paddock, M. N., Field, S. J., & Cantley, L. C. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092130 · Cited by 21 · see citing works

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,540 · see citing works

The phosphoinositide 3-kinase pathway and therapy resistance in cancer

Brown, K., & Toker, A. (2015) · F1000Prime Reports · doi:10.12703/p7-13 · Cited by 113 · see citing works

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 30 · see citing works